Loading...
•
Jun 30, 2022
Adaptive Biotechnologies Q2 2022 Earnings Report
Reported financial results for the quarter ended June 30, 2022.
Key Takeaways
Adaptive Biotechnologies reported a strong second quarter with a 13% increase in revenue compared to the previous year, driven by growth in both the MRD and Immune Medicine businesses. The company is focused on expanding clonoSEQ adoption and prioritizing pharma partnering and drug discovery opportunities.
Revenue of $43.7 million for the second quarter 2022, representing a 13% increase from the second quarter 2021.
clonoSEQ test volume in the second quarter 2022 grew 53% versus the second quarter of prior year and 17% over the first quarter of 2022.
Received expanded Medicare coverage of clonoSEQ for assessment of MRD in patients with Diffuse Large B-Cell Lymphoma (DLBCL).
Signed a new pan-portfolio agreement with major partner for the use of clonoSEQ to measure MRD as a clinical endpoint.
Revenue by Segment
Forward Guidance
Adaptive Biotechnologies reiterates full year 2022 revenue to be in the range of $185 million to $195 million. We now expect full year 2022 operating expenses to be between $410 million and $415 million compared to the previous expectation of $425 million to $435 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...